Eli Lilly

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

UK spurs prescribing of obesity jab Mounjaro with GP bonus

Doctors in the UK will be given thousands of pounds in bonus payments from April for prescribing Eli Lilly's weight-loss drug Mounjaro.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

Lilly says orforglipron tops Novo pill in diabetes trial

Novo Nordisk to cut GLP-1 prices in tough US market

Astellas bets on Vir cancer drug, and other licensing deals

UK spurs prescribing of obesity jab Mounjaro with GP bonus

FDA clears first all-oral combo for first-line CLL treatment

Head-to-head trial dents Novo Nordisk's obesity hopes

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks